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Expression of type 1 plasminogen activator inhibitor in renal
tissue in murine lupus nephritis
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Expression of type 1 plasminogen activator inhibitor in renal tissue in
murine lupus nephritis. Many renal diseases are associated with fibrin
deposition in the glomeruli, a situation that reflects an abnormality in the
balance between the coagulation and fibrinolytic systems. We recently
demonstrated that normal mouse kidney contains very low levels of type 1
plasminogen activator inhibitor (PAl-i), a potent anti-fibrinolytic protein,
but that during endotoxemia, large amounts of PAl-i protein and mRNA
are expressed in glomerular and peritubular endothelial cells. These
results raise the possibility that overexpression of PAT-i in the glomerulus
may contribute to the ongoing pathology seen in renal disease. To directly
investigate this possibility, we studied PAT-i expression in MRL/lpr mice,
using in situ hybridization and immunohistochemistiy. Female MRL/lpr
mice develop early onset lupus glomerulonephritis (GN), a disease in
which fibrin deposition is detected in the glomerulus and in which
anti-coagulation therapy improves the prognosis. We detected very low
levels of PAT-i mRNA and antigen in the smooth muscle cells of renal
vessels and in the renal papilla of 16 control mice. In contrast, PAT-i was
expressed in relatively high levels throughout the kidneys of 33 Out of 34
diseased mice, both within the glomerulus and also in tubules and vessels.
Moreover, the level of PAT-i in the tissues seemed to correlate with the
severity of the disease. PAl-i expression was localized to endothelial cells,
parietal epithelial cells, tubular epithelial cells and infiltrating mononu-
clear cells in the tubulointerstitium. None of these cells express detectable
levels of PAT-i in the normal kidney. The inappropriate expression of
PAl-i in the kidneys of mice with lupus GN suggests that this important
inhibitor of fibrinolysis may play a role in the pathogenesis of this disease
process.
Systemic lupus erythematosus (SLE) is an autoimmune disor-
der in which 70% of the patients develop auto immune glomer-
ulonephritis (GN). An interesting feature of GN in patients with
SLE is the endothelial cell activation and proliferation that
accompanies the disease, with subsequent intravascular coagula-
tion [1—3]. This pattern of disease suggests that endothelial cells
may play a central role in the process of coagulation. We have
recently shown that endothelial cells produce large amounts of
type 1 plasminogen activator inhibitor (PAl-i) in response to
lipopolysaccharide (LPS) [4], and it is known that LPS can
accelerate the progress of lupus GN in susceptible mice [5, 6].
PAl-i is a potent anti-fibrinolytic molecule by virtue of its
inhibition of both tissue-type plasminogen activator (t-PA) and
urokinase-type plasminogen activator (u-PA) [7], and local in-
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creases in PAl-i may be expected to inhibit the clearance of fibrin
at sites of coagulation. Thus, PAl-i expression by renal cells in
response to LPS or cytokines released in the inflammatory process
could lead to the progression of the disease.
We have been interested in the role of PAl-i in renal disease
since increased plasma PAl-i levels also correlate with the active
phase of a variety of human renal disorders, including the
nephrotic syndrome [8] and the hemolytic uremic syndrome [9].
Moreover, a large increase in plasma PAl-i was observed in an
experimental model of ON in which rats were injected with
anti-glomerular basement membrane (anti-GBM) antibodies [10].
Microscopic examination of renal tissue from these animals
showed fibrin thrombi in glomeruli. In this same study, direct
administration of TNFa also caused large increases in plasma
PAl-i, and concomitant administration of both the nephrotoxic
antibody (Ab) and TNFcs caused super induction of plasma PAI-l
levels. The increase in PAl-i was again associated with an
increase in fibrin thrombi. Although the expression of PAl-i
during the acute phase of these diseases could account for early
decreases in fibrinolysis, the role of PAl-i in ongoing chronic
glomerulonephritis remains to be determined.
In this report, changes in renal PAl-i in a murine model [11—13]
of SLE in MRLI1pr female mice were investigated. PAl-i was
expressed in relatively high levels throughout the kidneys of 33 out
of 34 diseased mice, both within the glomerulus and also in
tubules and vessels. Serological parameters [anti-double stranded
DNA antibodies (Ab), anti-single stranded DNA Ab, anti-chro-
matin Ab and anti-histone Ab] and histopathological examination
of kidneys confirmed that the mice with elevated PAl-i expression
had active lupus GN. This increase in PAl-i expression could
promote the increased fibrin deposition associated with lupus
nephritis.
Methods
Tissue preparation
Female diseased mice (34 MRLI1pr mice aged 4 months to 7
months) and female control mice [10 MRL/scr and 6 CB6 mice
(Balb C/ByJ x C57B16/J aged 4 months to 18 months), Scripps
Clinic Rodent Breeding Colony] were sacrificed by overdose
inhalation anesthesia using metofane. Blood was drawn from the
left ventricle, anticoagulated with 0.01 M citrate, centrifuged at
4000 g for 15 minutes, and then the plasma was removed and
stored at —70°C. Various organs were removed, quickly immersed
in freshly prepared 4% paraformaldehyde at 4°C overnight,
embedded in paraffin blocks, and then sectioned at 2 to 5 m
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thickness using a microtome. The tissue sections were mounted
onto polylysine slides and stored at room temperature. PAS stains
were performed using standard techniques.
ELISA assays
The substrates for the ELISAs to define serological parameters
were made from calf thymus (Pet Freeze, Rogers, AR) exactly as
previously described [14]. Briefly, long soluble chromatin stripped
of histone Hi and non-histone proteins, and thus consisting
essentially of DNA wrapped around the (H2A-H2B-H3-H4)2
histone octamer, was made by washing chromatin in 0.5 M NaC1
[15]. The native histone octamer was prepared by salt extraction
of chromatin [16], and DNA (Calbiochem, La Jolla, CA, USA)
was further purified by proteinase K digestion, extraction with
phenol, and digestion with Si nuclease as described [14, 17].
Single stranded DNA was made by placing this DNA into a
boiling water bath for 15 minutes and then cooling rapidly in ice
water.
The ELISA was performed as previously described in detail [14,
17], except the plates were coated with 100 p.1 instead of 200 p.1 of
antigen in each well. In addition, methylated BSA was pre-coated
on the ELISA plate before binding both double-stranded and
single-stranded DNA. Sera were diluted 1:300 in serum diluent
(1% gelatin, 1% BSA, 0.75% BGG, 0.05% tween-20, in 0.14 M
NaC1, 0.1 M sodium phosphate, pH 7.4) and 100 pi was incubated
in duplicate in the ELISA at room temperature for two hours.
After washing, the plates were incubated for two hours with goat
anti-mouse class specific antibodies conjugated with horseradish
peroxidase (Caltag, South San Francisco, CA, USA). The detect-
ing antibody was quantified with the 2,2'-azino-di-[3-ethylbenz-
thiazolinsulfonate] (Boehringer Mannheim, Germany) colorimet-
nc reagent as described [17].
Riboprobe preparation
A full length mouse PAl-i cDNA ([18] sub-cloned into the
vector pBS + (Stratagene) was provided by Drs. L. Diamond and
M. Cole (Princeton University). An EcoRI/SphI fragment con-
taining from nucleotide 1 to nucleotide 1085 of the mouse PM-i
eDNA was cloned into pGEM-3Z (Promega). This vector was
linearized with the restriction enzyme EcoRI and used to make an
antisense riboprobe labeled with 35S-labeled UTP (specific activ-
ity, 1200 Ci/mmol; Amersham) by in vitro transcription using SP6
RNA polymerase (Promega). The DNA template was removed by
digestion using RQ1 DNAse for 15 minutes at 37°C and the
riboprobe purified by phenol extraction and ethanol precipitation.
This vector also was used to make a sense control probe by in vitro
transcription using T7 RNA polymerase following linearization
with the restriction enzyme Hindill.
In situ hybridization
In situ hybridizations were carried out essentially as described
[19]. Briefly, prior to hybridization, the paraffin sections (2 to 5
p.m) were pretreated sequentially with xylene (three 5 mm
washes), with 2x SSC (one 10 mm wash; ix SSC = 150 mM
NaCI/i5 m sodium citrate, pH 7.0), with 4% paraformaldehyde
(10 mm at 4°C), and with proteinase K at 1 p.g/ml in 500 mrvi
NaC1/iO mM Tris-HCI pH 8.0 (10 mm at room temperature). The
slides were then pre-hybridized for two hours in 100 p.1 of
pre-hybridization buffer [50% (wt/vol) formamide/0.3 M NaCl/20
mM Tris-HC1, pH 8.0/5 mM EDTA/0.02% polyvinylpyrrolidone/
0.02% Ficoll/0.02% bovine serum albumin/10% (wt/vol) dextran
sulfate/iO mrvi dithiothreitol] at 42°C. The hybridizations were
started by adding 600,000 cpm of the 35S-labeled riboprobe in 20
p.l of pre-hybridization buffer containing 2.5 mg/ml of t-RNA, and
were carried out at 55°C overnight. The sections were then
washed with 2x SSC (2 10-mm washes), treated with RNase A (20
p.g/mI in 500 mM NaC1/lO msi Tris-HC1 for 30 minutes at room
temperature), washed in 2x SSC (2 10-mm washes), and then
washed at high stringency with 0.lx SSC at 60°C for two hours. All
SSC solutions up to this point of the procedure contained 10 mM
2-mercaptoethanol and 1 mrvi EDTA to reduce non-specific
binding of the probe. The sections were washed in 0.5x SSC
without 2-mercaptoethanol (2 10-mm washes), dehydrated by
immersion in a graded alcohol series containing 0.3 M NH4Ac,
dried, coated with NTB2 emulsion (Kodak; diluted 1:2 in water),
and exposed in the dark at 4°C for 2 to 12 weeks. Slides were
developed for two minutes in D19 developer (Kodak), fixed,
washed in water (3 5-mm washes) and counter stained with
hematoxylin and eosin. Parallel sections were analyzed using a
sense probe as the control for non-specific hybridization and in no
instance was a specific signal detected (data not shown).
Immunohistochemistry
Immunohistochemistry was done on cryostat sections using an
immunoperoxidase technique. Kidneys were embedded in OTC
and frozen in liquid nitrogen. Four micron sections were cut using
the cryostat, fixed with cold, 4% paraformaldehyde for five
minutes, washed with PBS (5 mm) and then with PBS-0.1% glycin
(5 mm). The sections were then incubated sequentially in avidin
(10 U/mI) and d-biotin (1 mg/ml) for 40 minutes each, and then in
blocking solution (reagent diluent; 2.5% heat inactivated horse
serum in PBS, pH 7.5) for 20 minutes. Primary antibody (rabbit
anti-mouse PAl-i, 40 p.g/ml in reagent diluent) was incubated on
sections in humidified chambers at room temperature (RT) for
two hours. Tissue sections were further incubated with peroxidase
conjugated goat anti-rabbit IgG (Jackson Immunology, 1:200 in
reagent diluent) for one hour at RT. Color reactions were
developed with aminoethyl carbozole (AEC) for 30 minutes,
counter stained with Mayor's hematoxylin, rinsed, and mounted
with Gelmount (Biomeda). The staining results were observed
using light microscopy.
In control experiments, tissue sections were stained with anti-
sera previously depleted of the specific antibodies. In the case of
PAT-I, immunoadsorption was performed by adding a 20-fold
molar excess of PAl-i antigen over antibody to the immunopuri-
fled rabbit anti-mouse PAT-i solution, and the mixture was
incubated overnight at 4°C. This mixture was then used instead of
the primary antibody for immunohistochemical staining. No spe-
cific staining was apparent in these control experiments.
Immunoelectron microscopy
Staining for PM-i antigen was performed using the avidin-
biotin method with slight modifications. Semi-thin renal sections
(30 p.m) were first fixed in 4% paraformalderhyde for one hour at
4°C and then incubated in blocking buffer (10 mi Tris-HC1, 2%
BSA and 0.02% saponin, pH 7.5) for one hour at room temper-
ature. The slide was incubated with the primary antibody (rabbit
anti-PAl-i diluted 1:100) overnight at 4°C, with biotinylated goat
anti-rabbit IgG (1:100) for four hours at RT, and then with
avidin-peroxidase complexes (1:200; prepared according to the
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Table 1. Summary of the histological findings and the in situ hybridization results for each region of the kidney in both the control mice (Ci to C6
= CB6 mice and C7 to C16 = MRLIscr mice) and the diseased mice (Dl to D35 = MRL/lpr)
The age of the mice in months is indicated in the second column and the grade of renal disease from 0 to IV (as outlined in the Results) is indicated
in the third column. Each sample was also evaluated for the extent of glomerular proliferation and sclerosis (Glom; column 4), the extent of crescent
formation (Cres; column 5), the extent of interstitial nephritis (Int; column 6) and the extent of vascular involvement (Vas; column 7) and these results
are expressed on an increasing severity scale from 0 to 4+. Sections of the slides were graded for the presence or absence of PAl-i mRNA in these same
regions by in Situ hybridization after 12 weeks exposure of the slides. The presence of PM-i mRNA in a specific region is indicated by the shaded blocks.
direction of the Vectastatin Elite ABC Kit; Vector Lab) for four
hours at room temperature. All reagents were made in reagent
diluent (0.05 M Tris-HC1, 0.15 M NaC1, 2% BSA, 1% heat-
inactivated human serum, 0.02% saponin, pH 7.5) and between
each step, the sections were washed with reagent diluent three
times for 15 minutes at room temperature. For color develop-
ment, diaminobenzidine (2 mg/mi) in TBS was used at RT for 45
minutes. The sections were then transferred into 0.1 M cacadylate
buffer, pH 7.4 for 15 to 60 minutes and dehydrated in graded
ethanol, and then embedded in Epon 8 12 Resin (TAAB Lab
Equipment LTD, UK). Ultrathin sections were cut on an Ultra-
tome III (LKB Instruments Inc., Gaithersburg, MD, USA) and
mounted on 200 mesh bare grids and counter stained with uranyl
acetate. Osmium and lead acetate staining were not used because
of the possibility that they may obscure the diabenzidine reaction
product. The sections were examined and photographed with an
HV 12A electron microscope (Hitachi Ltd., Tokyo, Japan) at a
75-kV excitation power using a 20-gm objective aperture.
Results
Histopathology
Periodic Schiff Acid (PAS) staining was performed on renal
tissue from both diseased and control mice, and the glomeruli
were graded from 0 to IV (Table 1) as previously described [20].
In this grading system, a grade 0 is given to all specimens with no
glomerular lesions, grade I lesions show minimal mesangial
thickening, grade II lesions contain noticeable increases in both
mesangium and glomerular cellularity, and grade III lesions are
characterized by the preceding features plus superimposed in-
flammatory exudates and/or capsular adhesions. Grade IV lesions
are characterized by obliteration of glomerular architecture in-
volving > 70% of the glomeruli. The control mice (Cl to C6 =
CB6 and C7 to C16 = MRL/scr) showed no evidence of renal
disease (Grade 0 to I; Table 1) at all ages examined, whereas the
diseased mice (Dl to D35 = MRL/lpr) showed severe grades of
lupus GN (Grade II to IV; Table 1). Interstitial nephritis with
inflammatory mononuclear cells surrounding the glomeruli and
tubules was frequently detected (Fig. 1A). The glomerular lesions
were characterized by cell proliferation and inflammatory exuda-
tion accompanied by membrane thickening and crescent forma-
tion (Fig. 1B), and in many instances, severe polyarteritis involv-
ing the renal arteries was observed (Fig. 1C).
Disease markers
ELISA assays for autoantibodies including anti-double
stranded DNA, anti-single stranded DNA, anti-chromatin and
anti-histone were performed as described in the Methods section
[21]. MRLIIpr mice had an increase in all parameters compared to
control mice (Table 2) indicating that the MRL/lpr mice had
autoimmune disease [22]. We also examined creatinine levels but
found no significant difference between the control and the
disease group (0.4 vs. 0.3), indicating that the mice did not have
end stage renal failure.
No. Age Grade Gtom Cres mt Vas No. Age Grade Glom Cres
-
mt Vas
Ci 4 0
C2 6 0
C3 8 0
8 0
12 0
18 0
2 0
4 0
6 0
4 0
4 0
o a 0 0 Dli 5 lii 3+
o 0 0 0 1)12 5 Iii 3+
o 0 0 0 1)13 6 ii 3+
o 0 0 1)14 6 11 0
o 0 0 0 1)15 6 II 3+
o o 0 0 1)16 6 IV 3+
o o 0 0 D17 6 III 3+
o 0 0 0 1)18 6 IV 4+
o o 0 0 1)19 7 IV 4+
o 0 0
o o 0
C4
CS
C6
C7
CS
C9do
Cii
C1203
C14
dm5
06
Di
D2
D3
1)4
D5
1)6
D7
1)8
D9
DIO
+
2+
+
0
0
34-
4-F-
4-,-
0+ +
4 0 0 0
5 0 0 0 0
5 0 0 0 0
5 0 0 0 0
S I 0 0 0
2 0 0 0 0
4 0 0 0 0
5 III 4+ 0 3+
S Ii 3+ ÷ +
S IV 0 + • +
5 [11 4+ (I 2+
5 IV 4+ 2+ 3+
5 [11 4+ 0 +
5 IV 4±__2÷ a +
5 II 3+ 0 +
o D20
0 D21
0 D22
0 1)23
o 1)24
0 D25
0 D26
0 D27
0 D28
2+ D29
0 D30
o
--
D31
o D32
3+ 1)33
2+ 1)34
2+ D35
3+
7 IV 4+ 3+ 3+ 3+
7 III 3+ + 3+ 3+
7 II 2+ 0 + 2+
7 LV 4+ 3+ 2 2-1-
7 III 3+ 2+ 2+ 3+
7 II 2+ + + 3+
7 ILl 3+ + 0 2+
7 IL 3+ 0 2+ 2+
7 III 3+ + 2+ 3+
7 II 3+ (1 + 2+
7 III 3+ + + 2±
7 II 3+ 0 2+ 2+
7 III 3+ ; + 2+ 2+
7 II 3+ 0 + 2+
7 III 3+ 0 + 3+
7 III 4+ 0 + 3+
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Fig. 1. Histologic analysis of renal tissue from a MRL/lpr mouse. Panels show paraffin sections from the kidney of a MRL/lpr mouse stained with PAS
as described in the Methods. A Cortex with surrounding interstitial nephritis (arrows show areas of inflammatoly infiltrate) (bOX). B Glomeruli (G)
with crescent formation and hypercellularity (Arrow denotes a crescent) (200x). C Cortex with a glomerulus and an artery (L denotes the lumen) with
arteritis and a cuff of inflammatory cells (I) (200X). Photographs were taken using bright field microscopy.
Fig. 2. Localization of PA I-i mRNA in the cortex of mice with lupus GN. Renal cortex from control mice (A, 250X), and MRL/lpr mice (B and C, 400X)
were analyzed by in situ hybridization as described in the methods using an 35S labeled mouse PAl-i antisense riboprobe. Slides were exposed for 6
weeks at 4°C and then stained with hematoxylin and eosin. Panel A shows glomeruli (G) and tubules (T) of a control mouse with no visible in Situ
staining; Panel B is the glomerulus (G) of lupus GN mouse with an early lesion (grade I) showing hypercellularity and positive staining of parietal
epithelial cells (Arrow heads denote positive parietal cells) as well as positive cells in the glomerulus itself. The inset shows positive cells adjacent to
glomerular capillary loops (arrows denote possible endothelial cells, 1000X). Panel C shows a glomerulus (G) from a more advanced lesion (grade II)
with positive parietal epithelial cells (arrow heads denote positive cells) as well as positive cells in the surrounding inflammatory infiltrate (arrows denote
unidentified positive cells). D A section of renal cortex with a glomerulus from an advanced lesion (grade 3) processed by immunohistochemistry for
PAT-i antigen (400X).
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Table 2. ELISA assays to measure markers of disease activity in both
control mice (numbers Cl to C9 in Table 1) and in diseased mice
(numbers D4 to D8 and D18 to 27 in Table 1)
Assay Control OD (N = 9) Disease OD (N = 15)
Anti-ds DNA Ab 0.02 0.02 1.19 1.17
Anti-ss DNA Ab 0.20 0.056 5.08 2.03
Anti-chromatin Ab 0.003 0.009 4.06 2.06
Anti-histone Ab 0.29 0.16 1.83 2.06
The ELISA assays were performed as described in the Methods and the
results are expressed as the average optical density (OD) reading SD for
each group after background subtraction.
Localization of PAl-i by in situ hybridization and
immunohistochemisty
All regions of the kidney were examined for PAl-i mRNA
using in situ hybridization and for PAl-i antigen using immuno-
histochemistry. As described previously, the muscular wall of
renal vessels in the control animals [4] and the renal papilla (data
not shown) showed a weak hybridization signal, but only after 12
weeks exposure of the slides. The positive cell type within the
papilla has not been determined. All other regions of the kidney
including the glomeruli, were negative for both PAl-i mRNA
(Fig. 2A) and antigen, regardless of the age of the animals.
In contrast to the weak signal detected in control animals, large
amounts of PAl-i mRNA and PAl-i antigen were detected in
kidneys of MRL/lpr mice (below). In these instances, the hybrid-
ization signal could be detected after only two weeks exposure of
the slides. PAl-i positive cells were found in four main areas of
disease, including the tufts of glomeruli, the crescents of glomer-
uli, in areas with interstitial nephritis and finally, in vessels with
vasculitis.
Glomeruli
Close examination of the glomeruli revealed that PAl-i positive
cells were frequently located within relatively normal appearing
areas of the glomerulus (Fig. 2B; arrow heads mark such an area)
as well as in late proliferative lesions (Fig. 2C). These positive
cells were mononuclear and could represent either mesangial cells
or infiltrating inflammatory cells. These same regions of the
glomerulus were also positive for PAl-i antigen (Fig. 2D). Some
of the positive cells had the appearance of capillary endothelial
cells (Fig. 2B, C; arrows denote possible endothelial cells which
were frequently found adjacent to glomerular capillary loops; Fig.
2B, inset); this was confirmed by immunoelectron microscopy
(Fig. 3). For example, Figure 3A shows a low power view of an
endothelial cell stained for PAl-i antigen (arrow heads indicate
positive DAB staining). Examination of this section at a higher
power (Fig. 3B) shows the presence of intracytoplasmic vesicles
which stained for the PAl-i antigen.
A positive signal for PAl-i mRNA was also detected in areas of
crescent formation (Figs. 2B, 4A), and in the early stages of the
disease the positive cells appeared to be parietal epithelial cells
since they lay on the luminal side of Bowmans capsule. We were
unable to identify the cell type in later lesions due to the increased
amount of inflammatory mononuclear cells. Once again, the
presence of PAT-i antigen was detected in these same areas
(Fig. 4B).
Tubules
A number of mice also showed signs of inflammatory interstitial
nephritis (Fig. 5). These lesions were characterized by the pres-
ence of a cuff of inflammatory mononuclear cells surrounding the
tubular epithelial cells. In these cases, PAT-i mRNA was generally
detected within the tubular epithelial cells themselves (Fig. 5A,
B). The presence of PAl-i antigen in the renal tubules was
confirmed by immunoelectron microscopy (Fig. 6). This figure
shows a brush border of an epithelial cell with positive staining in
vesicles within the cytoplasm of the tubular epithelial cell.
Blood vessels
A necrotizing inflammatory arteritis was observed in many large
and medium size vessels. The media of these vessels was fre-
quently filled with inflammatory cells which had disrupted the
normal vessel architecture but had not apparently affected the
patency of the vessel. The media of these vessels had cells positive
for PAl-i mRNA (Fig. 7A) which showed a much more intense
signal than the vessels in control mice (not shown). In these
vessels, and in other more normal appearing vessels (Fig. 7B),
some endothelial cells (identified by their position on the luminal
side of the vessel wall) also stained positively for PAl-i mRNA.
Although positive endothelial cells were found at a relatively low
frequency within these vessels (usually 2 to 3 per section), their
presence is in contrast to the normal kidney in which endothelial
cells were entirely negative [4].
Comparison between the histologic grading of disease
and the distribution of PAl-i mRNA
Table 1 also summarizes the ages of the mice, the histologic
grading of disease in four separate regions of the kidney (namely
the glomerulus, the crescents, the interstitial nephritis and the
blood vessels), and whether these regions were positive for PAl-i
mRNA by in situ hybridization. Regions in which a positive in situ
hybridization signal was seen are indicated by shading of the
appropriate blocks. Control mice of the CB6 genetic background
(Cl to C6) showed no histological evidence of renal disease and
were negative for PAT-i mRNA in the regions described above.
Contro+. mice with the MRLIscr genetic background (C7 to C16)
were also negative for histologic evidence of disease except for
one 5-month-old mouse (C16) which showed grade I renal disease
with minimal mesangial thickening. These mice were all negative
by in situ hybridization for PAl-i mRNA. In marked contrast to
these observations using control mice, all the MRL/lpr mice
except the youngest (Dl) showed evidence of moderate to severe
Fig. 3. Immunoelectron microscopy for PAl-i antigen. Sections from the kidney of 20-week-old female MRLIIpr mice were processed by the
immunoperoxidase technique for PM-i antigen using DAB substrate as described in the methods. A A low power view of the glomerulus with positive
staining of an endothelial cell [2000x; EC denotes the endothelial cells, Epi. denotes the epithelial side of the basement membrane with podocytes (P)
of the mesangial epithelial cell. Arrows indicate positive DAB staining]. B A high power view of the same cell as shown in A in which intracytoplasmic
deposits of PAl-i antigen were visualized (7000x; BM denotes the basement membrane with podocytes on the epithelial cell side and positive staining
on the endothelial cell side. Arrows indicate positive DAB staining).
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Fig. 4. Localization of PAl-i mRNA and antigen in crescents of MRL/Ipr mice. A A glomerulus (G) with early crescent formation analyzed by in situ
hybridization (arrows heads denote positive staining of parietal epithelial cells). B A glomerulus with more advanced crescent formation, processed for
PAT-i antigen (G denotes the glomerulus and I denotes the surrounding inflammatory cells). Photographs were taken using polarized light
epiluminescence or bright field illumination.
Fig. 5. Localization of PAl-i in the renal medulla of MRL/lpr mice. Renal medullary sections were processed by in situ hybridization for PM-i as
described in Fig. 2. A An area of inflammation and tubule destruction with PAl-i positive cells (250x) (Arrow heads denote tubules with positive
staining) as well as some normal tubules which are PAT-i negative. B A tubule (T) with minimal inflammatory changes and PAl-i positive epithelial
cells (400X). Photographs were taken using polarized light epiluminescence.
Fig. 7. Localization of PAl-i in renal vasculature in MRL/lpr mice. Sections containing renal vasculature were processed by in Situ hybridization for PM-i
as described in Fig. 2. A An artery with strong staining in the media of the vessel wall (L denotes the lumen filled with red blood cells and T denotes
the surrounding tubules) (250x). B A high power view (400X) of the vessel wall with positive cells in the media (arrows denote positive smooth muscle
cells). The arrowhead denotes a positive endothelial cell identified by the characteristic luminal position and elongated shape. Photographs were taken
using polarized light epiluminescence.
Fig. 6. Immunoelectron microscopy for PAl-i antigen in MRL/lpr mice. Sections were processed for immunoelectron microscopy as described in Figure
3. A A low power view (2000x) of a proximal convoluted tubule (N denotes the nucleus) with the lumen (L) and brush border (BB). PM-i antigen
staining is indicated by the arrows.
lupus GN (grade II to IV). Moreover, most of the areas with chronic renal diseases [2, 3, 8—10, 28], little is known about the
severe disease were also positive for PAl-i mRNA. role of these fibrinolytic components in the progression of renal
disease. PAl-i, a potent anti-fibrinolytic protein which inhibits
Discussion both t-PA and u-PA, may be important in this regard. For
A striking feature of many acute and chronic forms of glomeru- example, increased plasma levels of PAl-i have been detected in
lopathy is the formation of intravascular thrombi in the glomer- human renal diseases and in an experimental model of GN [8—10].
ulus [10, 23—27]. This characteristic is particularly prominent in The site of synthesis of PAl-i in these studies is unknown, but we
lupus GN [1, 2] where intravascular thrombosis is frequently have recently shown that both glomerular and peritubular endo-
detected together with endothelial cell and mesangial cell prolif- thelial cells in vivo have the capacity to synthesize large amounts
eration. Although an increasing number of studies correlate of PAl-i in response to endotoxin [4]. In other studies, increases
abnormalities in the fibrinolytic system with both acute and in PAl-i in models of GN have been associated with increases in
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fibrin thrombi in the glomeruli [10]. Finally, it has been shown
recently that ancrod, a venom derived enzyme that clots fibrino-
gen, only induces fibrin deposition in rabbits that have elevated
PAl-i levels. Rabbits with normal levels of PAl-i did not develop
fibrin thrombi following ancrod infusion [29]. These observations
raise the possibility that chronic expression of PAl-i in endothe-
hal cells could suppress the fibrinolytic system locally and thus
predispose to the intravascular coagulation frequently associated
with lupus GN.
To directly address whether PAl-i was inappropriately ex-
pressed in ongoing renal disease, we chose to study lupus GN in
female MRLI1pr mice between the ages of 4 and 7 months. Mice
with the MRL genetic background have a predisposition to
develop autoimmune renal disease [11]. A spontaneous recessive
mutation, lpr (lymphoproliferation) in this genetic background
leads to an early onset SLE like syndrome. In these studies, we
compared the expression of PAl-i in the kidneys of normal mice
(that is, CB6 mice and MRL/scr mice without the disease) to the
expression of PAl-i in mice with lupus GN (that is, MRLIIpr).
Histopathologic analysis of renal tissue from MRLI1pr mice
confirmed that these animals had active lupus GN (Fig. 1 A to C
and Table 2), whereas the control mice (MRLIscr and CB6, Table
2) did not. This histologic assessment was confirmed serologically
by measuring the concentration of markers of active SLE in the
plasma of these mice. MRLI1pr mice had significantly higher levels
of anti-double stranded DNA Abs, anti-single stranded Abs [21,
30], anti-chromatin Ab and anti-histone Abs [30] than did the
control groups (Table 1). Although we also measured serum
creatine levels, no significant difference was found between the
control group and the disease group. Thus, the mice with lupus
GN did not seem to be in terminal renal failure.
The normal mice had veiy low levels of PAT-i mRNA, and it
was specifically localized to the SMCs of medium size vessels and
to an unidentified cell type in the renal papilla (data not shown),
consistent with our previous findings [4]. However, and in marked
contrast to normal mice, mice with lupus GN had high levels of
PAl-i mRNA at many sites of active disease (Fig. 2 C and D, Fig.
4 A and B and Fig. 5A). For example, we identified PAl-i positive
endothelial cells by virtue of their characteristic position on the
luminal side of the vessel wall in blood vessels (Fig. 7B) at sites of
active disease. Immunoelectron microscopy also identified PAT-i
positive endothelial cells in the glomerulus (Fig. 3A, B). PAl-i
positive cells were also found in the glomerular crescents (Fig. 2B,
Fig. 4A), and in early crescent formation, it was possible to
identify PM-i positive parietal epithelial cells by their position on
the luminal side of Bowmans capsule (Fig. 4A). In more advanced
lesions we were not able to identify the positive cells because of
the high density of inflammatory monocytes within the crescents.
At sites of interstitial nephritis, both tubular epithelial cells (Fig.
5 A and B, Fig. 6 A and B) as well as an unidentified cell type in
the surrounding inflammatory cells (Fig. 5A) expressed PM-i.
Finally, large vessels with infiltrating inflammatory cells were also
positive for PAl-i in the media (Fig. 7A). This signal was seen at
shorter exposures compared to normal mice (2 weeks compared
to 12 weeks). Interestingly, we also saw PM-i expression in areas
of the kidney that showed relatively little evidence of active
disease (Fig. 2B and Fig. 4A). These areas showed no infiltrating
inflammatory cells and normal renal architecture, and yet were
strongly positive for PAl-i mRNA. This observation suggests that
PM-i expression may occur early in the progression of lupus GN.
It is interesting to compare the differences between PAT-i
mRNA expression in lupus GN to those seen after LPS adminis-
tration. In lupus GN there is chronic expression of PAl-i over
long periods of time (weeks to months) since almost all the
diseased mice show some degree of PAl-i expression. In contrast,
LPS induces a much more transient expression of renal PAl-i,
with a peak at three hours which returns to background by 24
hours [31]. In addition to this difference, the repertoire of cells in
the kidney which express PAl-i mRNA in these models is also
different. After LPS administration, the majority of the PAl-i
expression is by endothehial cells at all levels of the renal
vasculature. This result is in contrast to lupus GN where many
different cells types express PAl-i including endothelial cells,
parietal epithelial cells, tubular epithelial cells and also unidenti-
fied cells in areas of inflammatory infiltrates.
The wide spectrum of cells expressing PAl-i in the kidneys of
mice with lupus GN suggests that there may be a common
underlying mechanism directing this expression. In our study,
PAT-i producing cells are found in areas of active disease and it is
possible that the mononuclear cells at these sites [32] release a
cytokine that induces PAl-i expression in a wide variety of renal
cells. Studies of lupus GN in MRL/lpr mice have shown that TNFa
is expressed in the cortex of diseased kidneys but not in normal
kidneys [33], and that administration of TNFa at 4 months of age
can exacerbate the disease [34]. Macrophages isolated from mice
with lupus GN synthesize TNFa in vitro [33], raising the possibility
that TNF may be an important cytokine in the progression of
lupus GN. This and other data [20, 35, 36] suggest that TNFa may
be a critical cytokine in the pathogenesis of lupus GN.
Mononuclear cells in areas of inflammation may express other
cytokines as well, and these may account for the much more
widespread expression of PAl-i seen in lupus GN compared to
endotoxemia. For example, we have previously shown that trans-
forming growth factor beta (TGFI3) leads to large increases in
renal PAl-i mRNA [31] and that TGF/3 regulates the PAl-i
promoter through at least three different regions [4]. In many
models of renal disease as well as in human renal disease, TGFI3
appears to play a pivotal role in the pathological accumulation of
extracellular matrix [37—39]. Moreover, administration of either
anti-TGF/3 antiserum or decorin, a naturally occurring inhibitor of
TGFI3, during experimental GN, inhibits both accumulation of
extracellular matrix and histological manifestations of the disease
[40, 41], and blocks the expected increase in glomerular PAT-i
deposition. These results suggest that increases in PAl-i in renal
disease also may be due to TGFI3.
Taken together, these observations suggest that a number of
different cytokines may play a role in the ongoing damage of the
kidney via their ability to increase PAl-i and thereby reduce PA
activity. This change in the balance of the PA system would lead
to the accumulation of extracellular matrix that is seen in many
renal diseases.
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